Global Afamelanotide Market (2024–2032): USD 136.27M to USD 258.01M Growth at 9.1% CAGR Global Afamelanotide Market is expected to grow from USD 136.27 million in 2024 to USD 258.01 million by 2032, registering a strong CAGR of 9.1% during 2025–2032. Market expansion is fueled by rising cases of rare phototoxic disorders such as Erythropoietic Protoporphyria (EPP), increased awareness about orphan diseases, and advancements in melanocortin-based peptide therapies.Afamelanotide, marketed as SCENESSE®, is the first and only FDA- and EMA-approved treatment for EPP. By stimulating melanin production, it offers significant photoprotection and improves sunlight tolerance, making it a breakthrough therapy for patients suffering from severe light sensitivity. Clinical pipelines exploring applications in vitiligo, photodermatoses, and select neurological disorders are further expanding market potential.

Global Antibody-Drug Conjugates (ADC) Market Outlook to 2032: Innovations, Pipeline Growth & Opportunities at 5.1% CAGR global Antibody-Drug Conjugates (ADC) market, valued at USD 2,717 million in 2024, is projected to reach USD 3,815 million by 2032, growing at a CAGR of 5.1%. This expansion is driven by rising cancer prevalence, rapid advancements in ADC conjugation technologies, and an expanding pipeline of next-generation oncology therapies. ADCs deliver targeted cytotoxic payloads through monoclonal antibodies, offering a breakthrough in precision oncology with reduced systemic toxicity. The report provides in-depth insights into market dynamics, clinical pipeline trends, manufacturing challenges, competitive landscape, regional growth patterns, and strategic opportunities shaping the future of ADC innovation.

Global Blood Product Market: USD 29.86 Billion in 2025 → USD 51.54 Billion by 2032 (CAGR 8.1%) Global Blood Product Market is poised for strong growth, rising from USD 29.86 billion in 2025 to USD 51.54 billion by 2032 at a robust CAGR of 8.1%. This expansion is driven by the increasing prevalence of chronic and hematological disorders, advancements in transfusion medicine, expanding plasma-derived therapies, and rising healthcare demand across emerging economies. Blood products—including plasma, red cells, platelets, albumin, immunoglobulins, and coagulation factors—play a critical role in trauma care, surgeries, immune deficiencies, and complex disease management. As innovation, infrastructure, and regulatory harmonization continue to strengthen worldwide, the market is set to see sustained growth and broader therapeutic adoption. 📥 Download FREE Sample Report: Blood Product Market - View in Detailed Research Report

This is how you know conversion therapy is bullshit

Global Metabolism Drugs Market to Grow at 5.7% CAGR, Reaching USD 22.91 Billion by 2032 Global Metabolism Drugs market is experiencing steady expansion, driven by increasing prevalence of metabolic disorders, advancements in targeted therapies, and growing healthcare expenditure across both developed and emerging regions. According to a new report from Intel Market Research, the market—valued at USD 15,640 million in 2024—is projected to reach USD 22,910 million by 2032, advancing at a CAGR of 5.7% during 2025–2032. The report provides a comprehensive overview of key market dynamics including production and consumption patterns, segmentation by drug type and application, regional insights, market drivers, challenges, and competitive landscape. Get Full Report Here: Metabolism Drugs Market - Complete Analysis